Beovu is a prescription medication used to treat neovascular (wet) age-related macular degeneration (AMD). In 2019, Beovu was linked to vision loss and blindness occurring from occlusive retinal vasculitis, retinal artery occlusion, and intraocular inflammation. Novartis, the drug's manufacturer, has changed the label to reflect the previously undisclosed danger. The new label approved by the FDA warns patients of certain risks associated with taking the medication.
The American Society of Retina Specialist (ASRS) voiced concern over vasculitis in patients being treated with the medication in 2019. In response, Novartis initiated an internal review and created an external review committee to analyze the certain patient records who experience these serious symptoms. The review concluded that Beovu is associated with certain adverse events, including “retinal vasculitis” and “retinal vascular occlusion.”
Beovu is still on the market and has not been recalled, but the medication is associated with a number of condition. Some common side effects of Beovu include the following:
Broken Blood Vessels
Eye Pain and Inflammation
Now, Beovu has been linked to the following serious complications, so significant they can result in complete blindness:
Retinal vasculitis (inflammation of the vascular branches of the retinal artery);
Retinal artery occlusion (blockage of the retinal artery carrying oxygen to the retina); and
If you or a family member has experienced any of the foregoing symptoms after being prescribed Beovu, contact the dangerous drug attorneys at Neumann Law Group for a free consultation. You may be entitled to financial compensation.